Human papillomavirus infection

CarraShield Labs Issued Ground-breaking Patent for Anti-viral Gel Technology Used to Prevent HPV Infections

Wednesday, September 23, 2020 - 4:00pm

CarraShield Labs' patented gel technology was first tested in groundbreaking work at the National Cancer Institute.

Key Points: 
  • CarraShield Labs' patented gel technology was first tested in groundbreaking work at the National Cancer Institute.
  • The CarraShield gel technology opens up entirely new ways to help prevent HPV-induced cancers and warts above and beyond vaccines.
  • Current HPV vaccines only protect against up to 9 types of HPV virus out of over 200 HPV types.
  • The first product to contain CarraShield is Divine 9, a water-based personal lubricant used to help prevent HPV infections in women.

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Friday, September 18, 2020 - 12:32am

Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.

Key Points: 
  • Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.
  • In a publication submitted Monday, September 14 (now available on the bioRxiv preprint server ), the authors present a systematic study on rational vaccine design and evaluation of vaccine response in mice.
  • In particular, Zhu and his team propose a new spike antigen design (S2GHR2) and displayed it on several SApNPs as COVID-19 vaccine candidates.
  • In practice, we have seen similar performance from the Merck HPV Gardasil vaccine which is essentially a protein nanoparticle vaccine.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

Thursday, September 17, 2020 - 12:56am

ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.

Key Points: 
  • ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.
  • But Merck knew that Gardasil was neither safe nor effective at preventing cervical cancer, and worse, the company knew that Gardasil could cause a host of serious health issues."
  • Baum Hedlund Aristei & Goldmanis one of the nation's leading law firms representing victims who have sustained injuries after receiving the Gardasil HPV vaccine .
  • Since 1973, Baum Hedlund Aristei & Goldman has won over $4 billion in settlements and verdicts on behalf of clients across all areas of practice.

Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022

Wednesday, September 16, 2020 - 4:45pm

During the period we delivered positive Phase 1b/2 results with TG4001, which have given us the confidence to progress the clinical development of this therapeutic vaccine against HPV-induced cancers.

Key Points: 
  • During the period we delivered positive Phase 1b/2 results with TG4001, which have given us the confidence to progress the clinical development of this therapeutic vaccine against HPV-induced cancers.
  • We intend to provide more detail on these positive Phase 1b/2 study results in the coming months.
  • Our oncolytic virus TG6002 showed positive initial data in a Phase 1 trial, indicating that it induces the production of a chemotherapy agent in the tumor.
  • Transgene intends to pursue the development of TG4001 and is actively working on the preparation of a confirmatory clinical study.

HOOKIPA Pharma’s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article

Wednesday, September 16, 2020 - 12:45pm

It is currently in Phase 1/2 clinical trials (NCT04180215) for HPV16+ cancers alone and in combination with an approved checkpoint inhibitor.

Key Points: 
  • It is currently in Phase 1/2 clinical trials (NCT04180215) for HPV16+ cancers alone and in combination with an approved checkpoint inhibitor.
  • HPV-associated cancers, especially head and neck cancers, remain a significant health concern, as no curative therapies are currently available.
  • Human Papillomavirus, or HPV, is estimated to cause about 5% of the worldwide burden of cancers.
  • This includes approximately 99% of cases in cervical, up to 60% of head and neck, 70% of vaginal and 88% of anal cancers.

Microbix’s REDx™ Controls Attain Australian TGA Registration

Thursday, September 10, 2020 - 12:00pm

MISSISSAUGA, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs) TGA registration of these REDx Controls & REDxFLOQ products by Microbixs distributor, R-Biopharm, enables it to offer these workflow controls to Australian clinical labs.

Key Points: 
  • MISSISSAUGA, Ontario, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs) TGA registration of these REDx Controls & REDxFLOQ products by Microbixs distributor, R-Biopharm, enables it to offer these workflow controls to Australian clinical labs.
  • This registration permits the sale of Microbixs positive and negative sample workflow controls in support of testing for active COVID-19 disease in liquid vial format (REDx Controls) and on room-temperature stable dried swabs (REDxFLOQ).
  • The registration also includes Microbixs liquid vial format REDx Controls positives for high-risk Human Papilloma Virus (HPV) types 16, 18, 45, and corresponding negative sample.
  • As whole-genome controls, Microbixs QAPs support test accuracy regardless of what variety of nucleic-acid sequences a test targets across the viral genome.

Worldwide Cancer Vaccines Industry to 2027 - Featuring Advaxis, Amgen & Dynavax Technologies Among Others

Tuesday, September 8, 2020 - 4:45pm

Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.

Key Points: 
  • Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.
  • Preventive cancer vaccines are traditional cancer vaccines used in healthy people to prevent cancer.
  • In addition, increase in cancer vaccines usage combined with other therapies, surge in demand for cancer vaccines, the rise in public awareness toward benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines further fuel market growth.
  • By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines.

Global Cancer Vaccines Market (2020 to 2027) - by Technology, Type, Indication and End-user - ResearchAndMarkets.com

Thursday, September 3, 2020 - 5:20pm

Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.

Key Points: 
  • Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.
  • There are two types of vaccines available in market, namely, preventive cancer vaccines and therapeutic cancer vaccines.
  • In addition, increase in cancer vaccines usage combined with other therapies, surge in demand for cancer vaccines, the rise in public awareness toward benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines further fuel market growth.
  • By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines.